MULTIcentre evaluation of Single high-dose bolus TiRofiban versus Abciximab with sirolimus eluting sTEnt or bare metal stent in acute myocardial infarction.

Slides:



Advertisements
Similar presentations
A Prospective, Randomized Comparison of Paclitaxel-eluting TAXUS Stents vs. Bare Metal Stents During Primary Angioplasty in Acute Myocardial Infarction.
Advertisements

M. Valgimigli University of Ferrara Italy MultiStrategy Study design MultiStrategy Study design.
J. Mehilli, A. Kastrati, K. Huber, S. Schulz, J. Pache, C.Markwardt, S. Kufner, F. Dotzer, K. Schlotterbeck, J. Dirschinger, A. Schömig Abciximab in Patients.
Stone p2203/Abstract/ Conclusions
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
J. Mehilli, MD, G. Richard, F-J. Neumann, S. Massberg, K-L. Laugwitz, J. Pache, J. Hausleiter, I. Ott, M. Fusaro, T. Ibrahim, A. Schömig, A. Kastrati Deutsches.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,
Clinical Result Overview
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction.
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
CYPHER® Clinical Evidence in Acute Myocardial Infarction (AMI)
Presentation at a Non PCI Facility Requiring Transfer Does NOT Worsen Long-term Prognosis in Patients With STEMI Undergoing Primary Angioplasty. The HORIZONS-AMI.
HORIZONS AMI Trial H armonizing O utcomes with R evascular IZ ati ON and S tents In A cute M ycoardial I nfarction H armonizing O utcomes with R evascular.
M. Valgimigli, MD, PhD On behalf of 3T/2R Investigators Tailoring Treatment with Tirofiban in patients showing Resistance to aspirin and/or Resistance.
Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.
ISAR REACT 3 A. Kastrati, F.-J. Neumann, J. Mehilli, S. Schulz, G. Richardt, R. Iijima, R.A. Byrne, P.B. Berger, A. Schömig Bivalirudin Versus Unfractionated.
Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial Presented at AHA Scientific Sessions Nov. 15, 2000.
The Additive Value of Tirofiban Administered With the High-Dose Bolus in the Prevention of Ischemic Complications During High-Risk Coronary Angioplasty.
Maurizio Menichelli MD San Camillo Hospital, Rome ( SESAMI Trial) Maurizio Menichelli Presenter Disclosure Information Nothing to Disclose Randomized trial.
E. Di Lorenzo A.O.R.N. “S. G. Moscati” – Avellino - Italy LONG-TERM OUTCOME OF DRUG-ELUTING STENTS COMPARED WITH BARE METAL STENTS IN ST-SEGMENT ELEVATION.
Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.
CARDIOLOGIA INV 1 CAREGGI - FIRENZE Objective To determine whether nonresponsiveness to clopidogrel as revealed by high in vitro residual platelet reactivity.
New Horizons for Patients with ST-Elevation Myocardial Infarction Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation.
Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction STRATEGY Trial Journal of the American Medical.
Paclitaxel Eluting Stent Versus Conventional Stent in ST-segment Elevation Myocardial Infarction (PASSION) Trial Presented at The American College of Cardiology.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
Compare Trial 2 year follow-up Peter Smits Maasstad Ziekenhuis Rotterdam The Netherlands.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Randomized Early versus Late AbciXimab in Acute Myocardial Infarction treated with primary coronary intervention (RELAx-AMI Trial) Mauro Maioli M.D., Francesco.
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
Results From the MISSION! Intervention Study Sirolimus-Eluting Stents Vs Bare-Metal Stents in Patients With STEMI : 9-Month Angiographic and Intravascular.
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.
1 Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial N Engl J Med 2001;344:
Durable Polymer DES: 5 Year Outcomes RESOLUTE Update Sigmund Silber, MD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany On Behalf of the RESOLUTE.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,
Tailoring Treatment with Tirofiban in patients showing Resistance to
12 Month Outcomes in Patients with Diabetes Mellitus Implanted with a Resolute Zotarolimus-eluting Stent: Initial Results from the RESOLUTE Global Clinical.
M. Valgimigli University of Ferrara Italy
For the HORIZONS-AMI Investigators
On behalf of J. Belardi, M. Leon, L. Mauri,
Two-Year Extended Follow-up in Patients Receiving a Zotarolimus-eluting Stent in the E-Five Registry Martin T. Rothman, Ian T. Meredith, Keyur Parikh,
Statins Evaluation in Coronary procedUres and REvascularization
The American College of Cardiology Presented by Dr. Maurits T. Dirksen
The HORIZONS-AMI Trial
3-Year Clinical Outcomes From the RESOLUTE US Study
For the HORIZONS-AMI Investigators
For the HORIZONS-AMI Investigators
Five-Year Cumulative Rates of Clinical Events after Cypher™ Stent Implantation: Insights from a Patient-Level Pooled Analysis of Four Randomized Trials.
Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:
American Heart Association Presented by Dr. Julinda Mehilli
Impact of Platelet Reactivity Following Clopidogrel Administration
Erasmus MC, Thoraxcenter
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
What oral antiplatelet therapy would you choose?
On behalf of Multistrategy
Maintenance of Long-Term Clinical Benefit with
DEScover: One-Year Clinical Results
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

MULTIcentre evaluation of Single high-dose bolus TiRofiban versus Abciximab with sirolimus eluting sTEnt or bare metal stent in acute myocardial infarction studY MULTIcentre evaluation of Single high-dose bolus TiRofiban versus Abciximab with sirolimus eluting sTEnt or bare metal stent in acute myocardial infarction studY MULTISTRATEGY M. Valgimigli, MD, PhD On behalf of Multistrategy Investigators ClinicalTrials.gov number, NCT

Background There is limited data on the comparison between Abciximab vs. Tirofiban at high bolus dose (HDB: 25  g/kg over 3 min) 4 RCTs have so far contrasted these two drugs in 719 pts undergoing PCI of whom less than 300 were recruited in the setting of STEMI 1,2 The use of DES in the setting of STEMI is currently discouraged due to partially conflicting results on efficacy from MC-RCTs 3,4 and safety concerns from registries 5,6 1: Valgimigli et al. JAMA 2005; 2: Danzi et al. Am J Cardiol 2004; 3: Spaulding et al. NEJM : Laarman et al. NEJM 2006; 5: Spertus et al. Circulation 2006; Steg PG et al. ESC 2007

INCLUSION CRITERIA: Chest pain for >30 min with ST- segment elevation ≥1 mm in two or more contiguous leads, or with a new left bundle-branch block Admission either within 12 h of symptom onset or between 12 and 24 h after onset with evidence of continuing ischemia EXCLUSION CRITERIA: Those related to controindications to the use of glycoprotein IIb/IIIa inhibitors INCLUSION CRITERIA: Chest pain for >30 min with ST- segment elevation ≥1 mm in two or more contiguous leads, or with a new left bundle-branch block Admission either within 12 h of symptom onset or between 12 and 24 h after onset with evidence of continuing ischemia EXCLUSION CRITERIA: Those related to controindications to the use of glycoprotein IIb/IIIa inhibitors Trial Design Aspirin mg orally or 250 mg intravenously, followed by mg orally indefinitely Clopidogrel 300 mg orally and then 75 mg/day for at least 3 months Unfractioned Heparin (40-70 U/kg) Target ACT of at least 200 secs Aspirin mg orally or 250 mg intravenously, followed by mg orally indefinitely Clopidogrel 300 mg orally and then 75 mg/day for at least 3 months Unfractioned Heparin (40-70 U/kg) Target ACT of at least 200 secs No exclusion criteria based on: Haemodynamic Status Angiographic Findings

STEMI all-comer Patients Aspirin + Clopidogrel + UFH Before Arterial Sheath Insertion Aspirin + Clopidogrel + UFH Before Arterial Sheath Insertion Tirofiban*Tirofiban*AbciximabAbciximab SESSESBMSBMS Trial Design SESSESBMSBMS 1:1 Clinical FU 1, 4, 8 ms, 1yr and then yearly up to 5 Coronary Angiography±PCI Stenting was the default strategy in pts with a RVD≥ 2.5 mm at visual estimation *: given as a bolus of 25  g/kg, followed by an hour infusion at 0.15  g/kg/min

Study Primary Endpoints Pharmacology Arm ≥50%  ST segment elevation resolution within 90’ after last balloon tt-EKG Non-inferiority basis Stent Arm Cumulative rate of MACE, defined as overall death, Reinfarction or TVR within 8 months Superiority basis

Assumed event rates Endpoint Test Abciximab Tirofiban SES BMS  Power ≥  50% N-Inf. 85% 85% ─ ─ 9%* >85% STR MACE Sup. ─ ─ 16% 27% ─ 80% Study Primary Endpoints Power Analysis Study Primary Endpoints Power Analysis With 600 pts randomized and type I error *: ~50% of previously reported  ≥  50% STR between Abciximab vs. placebo in the ACE trial (Antoniucci et al. J Am Coll Cardiol 2003)

Study Organization Sponsor: University of Ferrara, Italy Data Management: Medical Trial Analysis, Switzerland Site and data monitoring: Medical Trial Analysis, Italy ; Sermes C.R.O., Spain Clinical Events Committee: P. Agostoni (Chair), Belgium, E. Meliga, The Netherlands. ECG core lab: MTA, C. Arcozzi (Chair) Angiographic core lab: MTA, P. Malagutti (Chair) DSMB: P. Vranckx, (Chair), Belgium

G Campo Ferrara R Moreno Madrid G Percoco Lagosanto T Piva Ancona M Anselmi Verona I Sheiban Torino L Bolognese Arezzo G Pasquetto Mirano S Colangelo Torino F Prati Rome N de Cesare Zingonia M Nazzaro Rome A Rodriguez B. Aires J Fernández Huelva M Ferrario Pavia J Mieres B Aires MULTISTRATEGY P.I.s and Sites

745 Randomized Abciximab and Uncoated Stent (n=186) Abciximab and Uncoated Stent (n=186) 1:1:1: Patients Assessed for Eligibility 285 Excluded 153 Not Meeting Inclusion Criteria 132 Refused to Participate Abciximab and Sirolimus-Stent (n=187) Abciximab and Sirolimus-Stent (n=187) Tirofiban and Uncoated Stent (n=186) Tirofiban and Uncoated Stent (n=186) Tirofiban and Sirolimus-Stent (n=186) Tirofiban and Sirolimus-Stent (n=186) N=186 N=186 N=186 N=186 8 month Follow-up Study N=179 N=182 N=184 N=177 ST Segment Resolution Study 1 pt withdrew consent 99% received Abciximab 97% received PCI 90% received Abc+BMS 99% qualified as STEMI 3% non-interpretable ECG 100% received Abciximab 99% received PCI 87% received Abc+BMS 100% qualified as STEMI 2% non-interpretable ECG 100% received Tirofiban 98% received PCI 95% received Tir+BMS 99% qualified as STEMI 1% non-interpretable ECG 100% received Tirofiban 98% received PCI 89% received Abc+BMS 99.5% qualified as STEMI 4% non-interpretable ECG 72% 97% 100%

Abciximab Tirofiban P BMS SES BMS SES Age (yr) 64.1 (55-74) 63.4 (55-70) 66.3 ( 57-75) 64.1 (54-74) 0.29 Male Sex (%) BMI (kg/m 2 ) 27 (25-29) 27 (25-29) 27 (24-29) 27 (24-29) 0.27 Diabetes (%) Hypertension (%) CrCl (ml/min) Prior MI (%) Prior PCI (%) Prior CABG (%) Prior CVA (%) Systolic Pres (mmHg) Heart Rate (bpm) LVEF (%) Killip class >1 (%) Symptoms to H (min) Door to balloon (min) Abciximab Tirofiban P BMS SES BMS SES Age (yr) 64.1 (55-74) 63.4 (55-70) 66.3 ( 57-75) 64.1 (54-74) 0.29 Male Sex (%) BMI (kg/m 2 ) 27 (25-29) 27 (25-29) 27 (24-29) 27 (24-29) 0.27 Diabetes (%) Hypertension (%) CrCl (ml/min) Prior MI (%) Prior PCI (%) Prior CABG (%) Prior CVA (%) Systolic Pres (mmHg) Heart Rate (bpm) LVEF (%) Killip class >1 (%) Symptoms to H (min) Door to balloon (min) Baseline Characteristics

Abciximab Tirofiban P BMS SES BMS SES 1-VD VD VD LAD-culprit RCA-culprit LMCA-culprit SVG-culprit Interventions De Novo culprit No. Stents Stent Length Max Stent Size 3.07± ± ± ± Stent post-dil Max Pressure 14.1± ± ± ± GP2b/3a infusion 12 (12-12) 12 (12-12) 24 (16-24) 24 (17-24) <0.001 ACT at peak ( ) ( ) ( ) ( ) Abciximab Tirofiban P BMS SES BMS SES 1-VD VD VD LAD-culprit RCA-culprit LMCA-culprit SVG-culprit Interventions De Novo culprit No. Stents Stent Length Max Stent Size 3.07± ± ± ± Stent post-dil Max Pressure 14.1± ± ± ± GP2b/3a infusion 12 (12-12) 12 (12-12) 24 (16-24) 24 (17-24) <0.001 ACT at peak ( ) ( ) ( ) ( ) Baseline Characteristics

Abciximab Tirofiban P BMS SES BMS SES RVD (mm) before PCI after PCI MLD (mm) before PCI after PCI % stenosis before PCI after PCI Abciximab Tirofiban P BMS SES BMS SES RVD (mm) before PCI after PCI MLD (mm) before PCI after PCI % stenosis before PCI after PCI QCA Analysis

ST Segment Resolution Rationale for choosing this endpoint in STEMI Circulation 2004;110(21):e Jama 2005;293(9): Eur Heart J Jun;28(12): ST segment resolution correlates with infarct size and infarct transmurality as assessed at MRI or SPECT ST segment resolution has strong and independent prognostic implications in terms of both death or the composite of death or MI Interventions in STEMI which improve ST segment resolution have a consistent effect on outcomes and viceversa Lancet 1997;350(9078):615-9 N Engl J Med Feb 7;358(6): J Am Coll Cardiol 2003;42(11): Jama 2005;293(9):

ST Segment Resolution Internal Validity Assessment of the Chosen 1° Endpoint P=0.023 at Log Rank test ST-Res ≥50% ST-Res <50%

ST Segment Elevation P=0.78 P=0.62  ST segment (mm) Number of ECG leads with ST Abciximab Tirofiban

Primary Endpoint ≥50%  ST segment resolution Abciximab Tirofiban H0: 85% 83.6% 85.3% P<0.001 for non-inferiority

Tirofiban Better Abciximab Better Prespecified Non-inferiority Limit Overall < 65 yr ≥ 65 yr Male Female Diabetes No Diabetes Killip class 1 Killip class ≥2 Single-vessel disease Double-vessel disease Triple-vessel disease Anterior Myocardial infarction Non Anterior Myocardial infarction Time to Tx ≤ 4 hr Time to Tx > 4 hr Creatinine Clearance ≥ 60 ml/min Creatinine Clearance < 60 ml/min RISK RATIO (95% CI) PRIMARY END POINT Tirofiban Abciximab % P-VALUE Non-inferiority Superiority Bare Metal Stent Sirolimus-Eluting Stent ° Endpoint: ≥50% ST segment resolution Subgroup Analysis < < < <0.001

ECG Analysis Core Lab Evaluation ECG Analysis Core Lab Evaluation N=722

30-Day Outcomes Efficacy Endpoints (CEC adjudicated) MACE Death/MI uTVR Definite Def/Prob Stent Thrombosis (ARC) Stent Thrombosis (ARC) P=0.85 P=0.98 P=0.59 P=0.56 P=0.22 Abciximab Tirofiban 4% 1% 2.5%

30-Day Outcomes Safety Endpoints (DSMB adjudicated) Major Minor RBC Tranfusion RBC Tranfusion Severe Any Thrombocytopenia P=0.44 P=0.40 P=0.82 P=0.03 P=0.004 Abciximab Tirofiban TIMI-Bleeding 2% 6% 4% 8% 0%

8 Month Outcomes MACE (CEC adjudicated) No. at Risk Abciximab Tirofiban

8 Month Outcomes Death/MI (CEC adjudicated) No. at Risk Abciximab Tirofiban

8 Month Outcomes Target Vessel Revascularization (CEC adjudicated) No. at Risk Abciximab Tirofiban

8 Month Outcomes MACE (CEC adjudicated) No. at Risk Uncoated Stent Sirolimus-Stent Adjusted HR: 0.53 (97.5%CI: ); p=0.006

8 Month Outcomes Target Vessel Revascularization (CEC adjudicated) No. at Risk Uncoated Stent Sirolimus-Stent

8 Month Outcomes Death/MI (CEC adjudicated) *: % SES patients taking dual antiplatelet treatment 82%*82%* 39%*39%* 32%*32%*

Uncoated Stent Sirolimus Stent Definite Definite/Probable Possible Definite/Probable Possible ARC Stent Thrombosis (CEC adjudicated) P=0.65 P=0.31 P=0.45 0% 1.5% 3% 4.5% 6%

Summary Our study provides evidence that in a broad population of largely unselected patients undergoing angioplasty for ST- elevation myocardial infarction: Tirofiban enables non-inferior STR within 90’ after intervention and similar outcomes at 8 months than Abciximab The MACE rate was approximately halved by the use of SES compared to BMS